Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2007-02-06
2007-02-06
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C424S094300, C530S378000, C435S188000
Reexamination Certificate
active
10253518
ABSTRACT:
Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
REFERENCES:
patent: 485749 (1992-05-01), None
Database Caplus DN 104:47840 Kamimura et al JP 60200169 Oct. 9, 1985.
Lutz et al Biochim Biophys Acta. Mar. 5, 1992;1116(1):1-10; see abstract.
Birmingham et al. J Lab Clin Med. Aug. 1990;116(2):242-52; see abstract.
Collen, D., “Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction”, 1996Circulation93:857-865.
Heeremans, J. et al., “The Preparation of Tissue-Type Plasminogen Activator (t-PA) Containing Liposomes:Entrapment Efficiency and Ultracentrifugation Damage”, 1995J. Drug Targeting3:301-310.
Higazi, A. et al., “Enhancement of the Enzymatic Activity of Single-chain urokinase Plasminogen Acitivator by Soluble Urokinase Receptor”, 1995J. Biol. Chem. 270:17375-17380.
Higazi, A. et al., “Single-Chain Urokinase-Type Plasminogen Activator Bound To Its Receptor Is Relatively Resistant To Plasminogen Activator Inhibitor Type 1”, 1996Blood87:3545-3549.
Kajihara, J. et al., “Physicochemical characterization of PEG-PPG conjugated human urokinase”, 1994Biochim. Biophys. Acta1199:202-208.
Muzykantov, V. et al., “Avidin Attachment to Biotinylated Erthrocytes Induces Homologous Lysis Via the Alternative Pathway of Complement”, 1991Blood78:2611-2618.
Muzykantov, V. and R. Taylor, “Attachment of Biotinylated Antibody to Red blood Cells: Antigen-Binding Capacity of Immunoerythrocytes and Their Susceptibility to Lysis by Complement”, 1994Anal. Biochem. 223:142-148.
Muzykantov, V. et al., “Regulation of the Complement-Mediated Elimination of Red Blood Cells Modified with Biotin and Strepatavidin”, 1996Anal. Biochem. 241:109-119.
Muzykantov, V. et al., “The Functional Effects of Biotinylation of Anti-angiotensin-Converting Enzyme Monoclonal Antibody in Terms of Targetingin Vivo”, 1995Anal. Biochem., 226:279-287.
Muzykanotv, V. et al., “Targeting of Antibody-Conjugated Plasminogen Activators to the Pulmonary Vasculature”, 1996J. Pharm. Exp. Ther., 279:1026-1034.
Runge, M. et al., “Enhanced Thrombolytic and Antithrombotic Potency of a Fibrin-Targeted Plasminogen Activator in Baboons”, 1996Circulation94:1412-1422.
Suzuki, T. and G. Dale, “Biotinylated Erythrocytes: In Vivo Survival and In Vitro Recovery”, 1987Blood70:791-795.
Zaltman, A. et al., “Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor”, 1995Biochem. J. 307:651-656.
Cines Douglas
Higazi Abd Al-Roof
Murciano Juan Carlos
Muzykantov Vladimir R.
Taylor Ronald P.
Borin Michael
Licata & Tyrrell P.C.
Trustees of the University of Pennsylvania
University of Virginia Patent Foundation
LandOfFree
Compositions and methods for prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3856724